PubHawk
N Engl J Med November 2018 PMID 30403574

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington, J Wouter Jukema, Guillaume Lecorps, Kenneth W Mahaffey, Angèle Moryusef, Robert Pordy

Full text PDF Download social card

Mentions

198
Peak: 6 in Jan 2019
across 5 sources since Nov 2018

Extended reach

492,783
potential audience

Total likes

2,229

Video views

54,356

Mentions per month

Nov 2018 – Nov 2025

Where it's discussed

  • News88 articles
  • X / Twitter74 posts
  • Facebook22 posts
  • Blogs8 articles
  • YouTube6 videos

AI synopsis

What people are saying

In the discussions, many users mention the implications of the ODYSSEY trial, emphasizing phrases like 'groundbreaking' and 'significant reduction' to underscore the importance of the findings. Users also engage with deeper statistical analyses, such as discussing the NNT (number needed to treat) for preventing cardiovascular events, demonstrating both interest and methodical engagement with the content. This choice of language, coupled with a semi-technical tone, reflects a blend of professional interest and general enthusiasm toward the research outcomes.

AgreementModerate agreement

The posts generally reflect a positive view towards the findings reported in the publication, with many quoting and supporting the conclusions drawn from the study.

InterestHigh interest

There is a strong curiosity among users, as noted by frequent references to related trials and ongoing discussions about the medication.

EngagementModerate engagement

While there is some deep engagement, particularly with users referencing study designs and statistical analysis, other posts show a more casual interaction with the content.

ImpactHigh impact

Many discussions highlight the potential significant impact of alirocumab on cardiovascular health, citing its effect on serious cardiovascular events and suggesting changes in treatment protocols.

Abstract in brief

  • The study investigated if alirocumab, a monoclonal antibody aimed at lowering LDL cholesterol, could enhance cardiovascular outcomes in patients recovering from acute coronary syndrome while on high-intensity statin therapy.
  • A large-scale, randomized trial included 18,924 patients and compared the effects of alirocumab versus placebo over a median follow-up of 2.8 years, targeting low LDL cholesterol levels.
  • Results showed that patients receiving alirocumab had a lower occurrence of serious cardiovascular events (9.5% vs. 11.1% in the placebo group), indicating a significant reduction in risk and associated mortality benefits.
Read the full abstract

Top posts

Most liked on X and Bluesky
Dr. Ozan Ünlü
@DrOzanUnlu · X

FOURIER

Mar 20, 2024 · 18 likes · 36,631 followers View post →
Melannie Ponce
@PonceMelannie · X

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome https://t.co/QBqfgUU3p9 via @YouTube

May 14, 2021 · 17 likes · 1 followers View post →
Ethan J. Weiss
@ethanjweiss · X

@sciencescanner I’ll dig in but honestly a little skeptical of these sorts of post-hoc exercises. It also defies all other data showing robust benefits of PCSK9I either genetically or pharmacologically including most importantly this: https://t.co/HHlx3ga0RZ

Jan 1, 2023 · 11 likes · 1 share · 30,110 followers View post →
Ethan J. Weiss
@ethanjweiss · X

@SBakerMD Does it make sense to want to reduce heart attacks or all-cause death? https://t.co/xtHCai9YcU https://t.co/BP6uT9Wo8U

May 21, 2025 · 9 likes · 30,110 followers View post →
gino yanqui
@YanquiGino · X

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome P... https://t.co/9BdRvCYGGr via @YouTube @mjack2050

Sep 17, 2021 · 9 likes · 19 followers View post →
cardio-met
@cardiomet_CE · X

21) Check out the great video summary at https://t.co/6GfIN8ASuL https://t.co/BaYMYrhbvm

Apr 26, 2022 · 8 likes · 1 share · 4,158 followers View post →

All mentions

Viet Le DMSc PA-C FACC FAHA HF-Cert
@VietHeartPA · X

RT @cardiomet_CE: 9c) #ODYSSEY OUTCOMES demonstrated that the monoclonal antibody #PCSK9 inhibitor #alirocumab significantly reduced ischem…

Aug 28, 2025 · 1 share · 9,791 followers View post →
cardio-met
@cardiomet_CE · X

9c) #ODYSSEY OUTCOMES demonstrated that the monoclonal antibody #PCSK9 inhibitor #alirocumab significantly reduced ischemic events in patients with a history of an acute coronary syndrome. See

Aug 26, 2025 · 3 likes · 1 share · 4,158 followers View post →
mikeMD
@MikeKon219 · X

@meg_texas @michael_hoerger Plenty of studies showing benefit of treating cardiovascular disease to lower LDL targets with statins +/- other medications with improved outcomes Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome | New England Journal of Medicine https://t.co/lUOV2sDDca

Jul 25, 2025 · 306 followers View post →
Ethan J. Weiss
@ethanjweiss · X

@SBakerMD Does it make sense to want to reduce heart attacks or all-cause death? https://t.co/xtHCai9YcU https://t.co/BP6uT9Wo8U

May 21, 2025 · 9 likes · 30,110 followers View post →
Austin Dudzinski, PharmD, BCACP
@ApoDudz · X

@euglycemic @thelowcarb_rd Both FOURIER (stable CAD, high risk) and ODYSSEY OUTCOMES (ACS) lowered MACE

Mar 11, 2025 · 1 like · 690 followers View post →
Daniel Ninio
@dninio · X

@Jikkyleaks @karrichapus @TonyNikolic10 @SabinehazanMD @rackusup @BroadbentMP @JohnRuddick2 @VirusFighterVi1 @AMPS_RedUnion @craigkellyXXX @PierreKory @DJSpeicher @toobaffled @SenatorRennick @PGtzsche1 @dystopian_DU https://t.co/ivUExQSwhn

Jan 22, 2025 · 212 followers View post →
Gil Carvalho MD PhD
@NutritionMadeS3 · X

@MohammedAlo @lrak456 statistical misunderstanding point estimate for ACM in FOURIER was 1.04, smack in the middle of the CI and p=0.54 in ODISSEY ACM did reach stat sig (a reduction of 15%), surprising for 2.8y followup https://t.co/EQR8hd9ViO https://t.co/4KVpOVGxWF

Nov 15, 2024 · 1 like · 27,740 followers View post →
manuel alfonzo
@malfonzop · X

RT @sigal_alan: Links para mas info: https://t.co/9Ani2CwOHe https://t.co/VW3LeD30zo https://t.co/BN70Bnt2jK https://t.co/1cknwROFf8 ht…

May 6, 2024 · 1 share · 777 followers View post →
Alan Sigal MD
@sigal_alan · X

Links para mas info: https://t.co/9Ani2CwOHe https://t.co/VW3LeD30zo https://t.co/BN70Bnt2jK https://t.co/1cknwROFf8 https://t.co/8oDAFUQ4Zh

May 6, 2024 · 7 likes · 1 share · 2,168 followers View post →
MIЯVΛƬ #IC ༄ ｡°
@mirvatalasnag · X

@assiri99 @KFAFHCards @fayezbaraah @Amgen @drptca @wagarhabib @Sultanotb @mohamed_elsabah @ibrahem_albakry The landmark trial specifically designed to capture outcomes in ACS was the Odyssey w Alirocumab @NEJM https://t.co/vkjujJn8tB

Apr 23, 2024 · 3 likes · 26,028 followers View post →
Dr. Ozan Ünlü
@DrOzanUnlu · X

FOURIER

Mar 20, 2024 · 18 likes · 36,631 followers View post →
maybeadoctor
@maybeadoc1983 · X

@Ikat0 @im_dori2 @Drlipid @jpapi7 https://t.co/nY7u8f5J3r NNT of like 200 to prevent 1 CV death. https://t.co/7PsE6feVcO No CV death improvement, NNT 100 to prevent an MI. Total mortality benefit likely noise given lack of CV death benefit (eg would mean it reduces infection or CA death better than CV).

Mar 18, 2024 · 4 likes · 87 followers View post →
Austin Dudzinski, PharmD, BCACP
@DudzLightLime · X

@JeffA47854828 @drpablocorral @Drlipid @MattBMartin @NEJM @JohnKastelein @society_eas @BNordestgaard @ProfKausikRay @LaleTokgozoglu @DrMarthaGulati @ErinMichos @rauldsf_santos @KarleziAlonso @Lpa_Doc https://t.co/NFsGAhmnQ2 https://t.co/XZOJKLUFAh https://t.co/01hDvJxldo https://t.co/SS9uD60C1Y

Jan 10, 2024 · 1 like · 866 followers View post →
Science Collected
@ScienceCollect1 · X

11/ Addition of #PCSK9 inhibitors to optimised #statin therapy further reduces #CV risk, but residual risk remains.

Oct 24, 2023 · 124 followers View post →
Wagner Felix
@astolfi_felix · X

RT @gabrielsteg: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome | NEJM https://t.co/jxIRQIpKG1

Sep 15, 2023 · 25 shares · 1,715 followers View post →
Andrea
@Andrea25633402 · X

@DoctorTro @DanClintonRN @Lipoprotein @MohammedAlo @professionaldog @dreamer_legal @trailrunner402 @degriffin10 @realDaveFeldman @Tellit007 @hightouchinv @Bernard22190947 Man this is embarrassing... It's the Odyssey outcomes: https://t.co/MWGY2or3Tw A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85; 95% CI, 0.73 to 0.98). Again, what's wrong with HR?

May 31, 2023 · 1 like · 18 followers View post →
Raphael Sirtoli
@raphaels7 · X

RT @raphaels7: fun debate w/ @DoctorTro yesterday! all-cause mortality in statins: HPSCG 2005 https://t.co/nmL25pLZFy, 4S trial 1994 https…

Mar 19, 2023 · 1 share · 8,595 followers View post →
BiotechObserver
@BiotechObserver · X

@Anthony41172027 @skathire Bempedoic acid did not show a mortality benefit and it had LONGER treatment duration and follow up. Praluent, on the other hand, did (with shorter treatment period). https://t.co/XTQPvDdkrc

Mar 5, 2023 · 2,794 followers View post →
Ethan J. Weiss
@ethanjweiss · X

@kaulcsmc @DLBHATTMD @rgiugliano @BartoszHudzik @bmj_latest @DrMarthaGulati @mmamas1973 @gbiondizoccai @HeartOTXHeartMD @drjohnm @cardskrish @Hragy @gina_lundberg @hvanspall @ErinMichos @iamritu @MKIttlesonMD @djc795 @AndrewJSauer @CMichaelGibson @TIMIStudyGroup Yes in that range. I guess I’m conforted by Oddssey https://t.co/xtHCai9qnm, the genetics and the design of these trials. In a parallel universe where PCSK9 inhibitors beat statins to the market, I’d predict we’d be having a very different conversation

Jan 15, 2023 · 4 likes · 30,110 followers View post →
JG FNP-BC
@soonergise · X

RT @ethanjweiss: @sciencescanner I’ll dig in but honestly a little skeptical of these sorts of post-hoc exercises. It also defies all other…

Jan 3, 2023 · 1 share · 247 followers View post →
BiotechObserver
@BiotechObserver · X

@KlendathuCap Derp. https://t.co/XTQPvDdkrc

Jan 2, 2023 · 2,794 followers View post →
Ethan J. Weiss
@ethanjweiss · X

@sciencescanner I’ll dig in but honestly a little skeptical of these sorts of post-hoc exercises. It also defies all other data showing robust benefits of PCSK9I either genetically or pharmacologically including most importantly this: https://t.co/HHlx3ga0RZ

Jan 1, 2023 · 11 likes · 1 share · 30,110 followers View post →
Ankur Sethi
@AnkurSethi2021 · X

@Umair2017 https://t.co/Vuntso5XWf

Oct 29, 2022 · 1 like · 182 followers View post →
Cristhyan Pacheco.
@Crizz_MD · X

@medinternajg Odyssey outcomes trial https://t.co/2shhYgv0Gc

Sep 27, 2022 · 1,907 followers View post →
cardio-met
@cardiomet_CE · X

27b)

Jul 20, 2022 · 2 likes · 4,158 followers View post →
Ahmed Mohsen
@drahmedmohsen85 · X

RT @cardiomet_CE: 21) Check out the great video summary at https://t.co/6GfIN8ASuL https://t.co/BaYMYrhbvm

Apr 26, 2022 · 1 share · 22,807 followers View post →
Ahmed Mohsen
@drahmedmohsen85 · X

RT @cardiomet_CE: 19) And then there's #alirocumab, studied in the #ODYSSEY OUTCOMES trial (

Apr 26, 2022 · 1 share · 22,807 followers View post →
cardio-met
@cardiomet_CE · X

21) Check out the great video summary at https://t.co/6GfIN8ASuL https://t.co/BaYMYrhbvm

Apr 26, 2022 · 8 likes · 1 share · 4,158 followers View post →
cardio-met
@cardiomet_CE · X

19) And then there's #alirocumab, studied in the #ODYSSEY OUTCOMES trial (

Apr 26, 2022 · 7 likes · 1 share · 4,158 followers View post →
Marilyn Mann
@MarilynMann · X

@ePatientDave @hcooperman1 @pheski Well, off the top of my head, since that blog post was written several things happened. The alirocumab (Praluent) trial was published. That's a PCSK9 inhibitor similar to evolocumab. https://t.co/qRxVznwcme

Mar 17, 2022 · 2,776 followers View post →
Viet Le DMSc PA-C FACC FAHA HF-Cert
@VietHeartPA · X

RT @cardiomet_CE: 29) The ODYSSEY OUTCOMES (

Feb 24, 2022 · 9,791 followers View post →
cardio-met
@cardiomet_CE · X

29) The ODYSSEY OUTCOMES (

Feb 24, 2022 · 4 likes · 4,158 followers View post →
Viet Le DMSc PA-C FACC FAHA HF-Cert
@VietHeartPA · X

RT @cardiomet_CE: 13) 2⃣ large outcome trials of PCSK9 monoclonal antibodies demonstrated significant ⬇️in CV events when added to #statin…

Feb 16, 2022 · 1 share · 9,791 followers View post →
Linda
@wordfinga · X

RT @cardiomet_CE: 13) 2⃣ large outcome trials of PCSK9 monoclonal antibodies demonstrated significant ⬇️in CV events when added to #statin…

Feb 15, 2022 · 1 share · 4,595 followers View post →
cardio-met
@cardiomet_CE · X

13) 2⃣ large outcome trials of PCSK9 monoclonal antibodies demonstrated significant ⬇️in CV events when added to #statin therapy:

Feb 15, 2022 · 8 likes · 1 share · 4,158 followers View post →
Viet Le DMSc PA-C FACC FAHA HF-Cert
@VietHeartPA · X

@SABOURETCardio @cpcannon @atishmathurmd @DLBHATTMD @atunuguntla1 @DrAnkitKPatel @jaymukherjeemd @purviparwani I do wish the Odyssey trialists had allowed the same. However, they had protocols to down titrate treatment for those who went below 25 mg/dL. https://t.co/GmI48A6Ji4 https://t.co/joKEVDXz9d

Feb 14, 2022 · 2 likes · 9,791 followers View post →
BiotechObserver
@BiotechObserver · X

@REV_Insulin_Res @NutritionMadeS3 If ApoB is the culprit, why did this work? https://t.co/M5wDrKuzm8 And before this, why did so many statin CVOTs work? ApoB is clearly not the only culprit, and LDL IS a culprit.

Jan 10, 2022 · 2,794 followers View post →
BiotechObserver
@BiotechObserver · X

@bohdyone @NutritionMadeS3 Facts are facts. But an autoimmune response??? LOL Probably not a good idea. It seems insane. https://t.co/M5wDrKuzm8

Jan 10, 2022 · 2,794 followers View post →
Raphael Sirtoli
@raphaels7 · X

fun debate w/ @DoctorTro yesterday! all-cause mortality in statins: HPSCG 2005 https://t.co/nmL25pLZFy, 4S trial 1994 https://t.co/J0EYwvWxGa, Kristensen 2015 https://t.co/KP5HqbmIdp And PCSK9i: FOURIER 2017 https://t.co/9hvNxT5SfS, Schwartz 2018 https://t.co/psJvTKidxz https://t.co/Wyjy2dsY4S https://t.co/uBwH9RGg3u

Jan 1, 2022 · 3 likes · 1 share · 8,595 followers View post →
Tom Babington
@Tom_Babington1 · X

@MacroFour @Plant_proof @AmandaZZ100 @ScepticalDoctor @dylanarmbruste3 @krosenque @NutritionMadeS3 @deirdre_tobias @realDaveFeldman @MacroEight @MattMadore576 @MyNutritionSci @drmatthewnagra @The_Nutrivore Here are PCSK9 inhibitors added to statin therapy, lowering LDL, and all cause mortality compared to placebo (just receiving statins) @The_Nutrivore may be able to share other relevant studies. https://t.co/4aw4xDRctS https://t.co/5rgjNAZBvw

Dec 28, 2021 · 2 likes · 1,202 followers View post →
Eric Sodicoff
@ESodicoffMD · X

@raphaels7 @DoctorTro https://t.co/k8JLqd9q3z https://t.co/kqJKuhdEK0

Dec 24, 2021 · 8,511 followers View post →
BiotechObserver
@BiotechObserver · X

@dbechek1 @Lpa_Doc @Drlipid @ionispharma 1. https://t.co/Io1MD7CU6O 2. https://t.co/M5wDrKuzm8

Nov 15, 2021 · 2,794 followers View post →
ZKForTre
@ZKForTre · X

https://t.co/bkiqHyT934 https://t.co/o6LOVbFaTr

Oct 7, 2021 · 1 like · 2,754 followers View post →
gino yanqui
@YanquiGino · X

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome reu... https://t.co/YqMGgkdRO8 via @YouTube @mjack2050

Sep 21, 2021 · 19 followers View post →
gino yanqui
@YanquiGino · X

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome P... https://t.co/9BdRvCYGGr via @YouTube @mjack2050

Sep 17, 2021 · 9 likes · 19 followers View post →
domesolexd
@domerockerita94 · X

RT @LostNic__: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome: https://t.co/Oi8UPCTe4T

Jun 29, 2021 · 2 shares · 751 followers View post →
Karolyne
@StylesKaro · X

RT @LostNic__: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome: https://t.co/Oi8UPCTe4T

Jun 29, 2021 · 2 shares · 394 followers View post →
Gláucio Mosimann Júnior
@JuniorMosimann · X

RT @ikramhaq_: Link to full papers: - https://t.co/rNWj11TxhX - https://t.co/DpDa8T81ak - https://t.co/WymzT1HeIg

Jun 28, 2021 · 2 shares · 41 followers View post →
Melannie Ponce
@PonceMelannie · X

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome https://t.co/QBqfgUU3p9 via @YouTube

May 14, 2021 · 17 likes · 1 followers View post →
Mohamad Bitar
@MoeBitar · X

RT @ikramhaq_: Link to full papers: - https://t.co/rNWj11TxhX - https://t.co/DpDa8T81ak - https://t.co/WymzT1HeIg

Apr 21, 2021 · 2 shares · 186 followers View post →
Ikram Haq, MD
@IkramHaqMD · X

Link to full papers: - https://t.co/rNWj11TxhX - https://t.co/DpDa8T81ak - https://t.co/WymzT1HeIg

Apr 21, 2021 · 4 likes · 2 shares · 925 followers View post →
Jason T Jodway
@Chimaera080 · X

@DaveKeto https://t.co/9IBKwVbBwV You can do the quick math. Death from cardiovascular causes: 240 to 271 Death from all causes: 334 to 392.

Oct 15, 2020 · 296 followers View post →
James Bui
@JamesBu27197516 · X

@ProfDFrancis I understand what you are trying to say the first time and the answer is the pcsk9 studies showed comparable / higher increase. Look at the bottom on page 30 of this appendix https://t.co/11d1jqAj7n. If i recall correctly water was the placebo in the PCSK9 study. Another Vexabo?

Sep 8, 2020 · 1 followers View post →
Patrick Mercié
@MerciePatrick · X

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome | NEJM https://t.co/jH67S0HYcs

Sep 8, 2020 · 1 like · 1,341 followers View post →
Christian Kjellmo
@ckjellmo · X

@holmanm @kevinnbass @OhhiyoGarmen @DrPaulMason @Drlipid @PeterAttiaMD @FatEmperor @DaveKeto @POhukainen @ArsenaultBenoit https://t.co/t73hEBkr4J

May 13, 2020 · 1 like · 187 followers View post →
Joysmom
@Haleymarie1569 · X

I’m bored but not I wanna read a 5 page research paper on “Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome” bored. Stupid professional school.

Mar 31, 2020 · 1 like · 191 followers View post →
Dr Jean Pierre Laroche #vacciné 6.0
@Echoraljpangio · X

RT @gabrielsteg: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome | NEJM https://t.co/jxIRQIpKG1

Mar 29, 2020 · 25 shares · 2,714 followers View post →
Guillaume Bonnet
@guilbon · X

RT @gabrielsteg: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome | NEJM https://t.co/jxIRQIpKG1

Mar 28, 2020 · 25 shares · 3,484 followers View post →
BiotechObserver
@BiotechObserver · X

@BioBoyScout @AndyBiotech Ignorance. It's not bliss. https://t.co/XTQPvDdkrc

Nov 17, 2019 · 2 likes · 2,794 followers View post →
JovSEN
@senjoven · X

RT @SVNefro: @EstebanDL @drfherediaz @jlgorriz @SVCardio @ValleAlfonso @Cokeino @SEHLELHA140_90 @SEMG_ES @semfyc @SEMERGENap @cristinatejer…

Oct 6, 2019 · 3 shares · 2,455 followers View post →
Marco Montomoli
@DrMontomoli · X

RT @SVNefro: @EstebanDL @drfherediaz @jlgorriz @SVCardio @ValleAlfonso @Cokeino @SEHLELHA140_90 @SEMG_ES @semfyc @SEMERGENap @cristinatejer…

Oct 6, 2019 · 3 shares · 927 followers View post →
SEH-LELHA
@SEHLELHA140_90 · X

RT @SVNefro: @EstebanDL @drfherediaz @jlgorriz @SVCardio @ValleAlfonso @Cokeino @SEHLELHA140_90 @SEMG_ES @semfyc @SEMERGENap @cristinatejer…

Oct 6, 2019 · 3 shares · 5,825 followers View post →
Sociedad Valenciana de Nefrología
@SVNefro · X

@EstebanDL @drfherediaz @jlgorriz @SVCardio @ValleAlfonso @Cokeino @SEHLELHA140_90 @SEMG_ES @semfyc @SEMERGENap @cristinatejerap @almucastro01 @sinaptopodina Fourier evolocumab https://t.co/LeBLpOEJYd Odyssey alirocumab https://t.co/FINFGozwVb

Oct 6, 2019 · 4 likes · 3 shares · 6,110 followers View post →
Dr. Deepak L. Bhatt
@DLBHATTMD · X

RT @gabrielsteg: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome | NEJM https://t.co/jxIRQIpKG1

Jul 6, 2019 · 25 shares · 39,867 followers View post →
SUNY Downstate School of Public Health (SPH)
@DownstateSPH · X

At today's Szarek Fellowship Awards Ceremony, Dr. Szarek discussed ODYSSEY OUTCOMES, a groundbreaking multinational clinical trial assessing the effectiveness of alirocumab for improving cardiovascular outcomes, recently published in @NEJM https://t.co/X2lmUcitOp https://t.co/67Nll6GoVQ

Jun 24, 2019 · 1 like · 688 followers View post →
J. Eulert-Grehn , MD
@EulertJ · X

RT @gabrielsteg: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome | NEJM https://t.co/jxIRQIpKG1

Apr 28, 2019 · 25 shares · 1,905 followers View post →
Morgan Pfiffner
@MorganPfiffner · X

@TuckerGoodrich @DrNadolsky @DaveKeto @ethanjweiss @puddleg This is: https://t.co/bctEdzwfJF

Apr 4, 2019 · 1,108 followers View post →
Bahaa Mustafa
@BahaaShq · X

@UMKCBioMed Alirocumab decreased the risk of recurrent ischemic cardiovascular events in comparison to placebo among patients who had a history of acute coronary syndrome and taking high intensity statin therapy #UMKCRCT https://t.co/OdLHQwaEwB https://t.co/wijlO71hRj

Mar 4, 2019 · 51 followers View post →
Stefania Arciello
@StefaniaArciell · X

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome | NEJM https://t.co/cdtPkv758q

Feb 1, 2019 · 3 likes · 1,945 followers View post →
KristopherMaday PA-C
@PA_Maday · X

ODYSSEY OUTCOMES Trial Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome https://t.co/VTYCg6T8eK https://t.co/Q3NJjwB7WR

Jan 27, 2019 · 2,460 followers View post →
Lorenzo Bertomeu
@ManuduManuel · X

RT @61Morillas: Publicación de reducción de eventos CV después de SCA con alirocumab en NEJM, que debe replantear las indicaciones de iPCSK…

Jan 23, 2019 · 6 shares · 3,593 followers View post →
Vimal Gokani
@VimalGokani · X

RT @a_saratzis: 4) Even more evidence favouring the use of PCSK9 inhibitors in high-risk patients. https://t.co/EKu42l9L16

Jan 12, 2019 · 1 share · 2,505 followers View post →
Athanasios Saratzis
@a_saratzis · X

4) Even more evidence favouring the use of PCSK9 inhibitors in high-risk patients. https://t.co/EKu42l9L16

Jan 11, 2019 · 1 like · 1 share · 4,068 followers View post →
movedoc
@movedoc · X

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome | NEJM https://t.co/ESlL7wqsRr

Jan 3, 2019 · 485 followers View post →